France-based Olfactive Biosolutions has secured the US patent for its novel food ingredient formulation, dubbed Protenx Weight Loss, for weight loss and blood sugar reduction.
Protenx Weight Loss is designed to activate olfactory receptors in the gut to induce the dual secretion of natural GLP-1 and GIP to enable weight loss and reduce blood sugar.
It will be offered as a supplement sold directly to consumers beginning in January 2025.
Food and beverage manufacturers can also incorporate Protenx Weight Loss into their products.
The formulation will offer benefits similar to prescription drugs without requiring changes in consumer behaviour or routines, and without side effects, said Olfactive Biosolutions.
Olfactive Biosolutions president and CEO Nils Lommerin said: “We are excited to have been granted this patent for Protenx Weight Loss, the first formulation in our line of Protenx products.
“The markets for reducing body weight and lowering blood sugar are very large, and our new product will help consumers tackle these conditions inexpensively and easily.”
Olfactive Biosolutions has engineered biosensor cells to behave like the ectopic olfactory and taste neuron cells in humans.
The company used the ectopic olfactory and taste receptor genes along with selected genes for intracellular signalling, for the biosensor cells.
The biosensor cells produce discreet, measurable luminescent signals when an engineered receptor on the cell’s surface binds to its complementary ingredient molecules.
Olfactive Biosolutions uses the technology to discover which food molecules activate or inhibit olfactory, taste and related receptors throughout the body to effectively treat several diseases.
